- Home
- FDMT vs ENGN Comparison
FDMT vs ENGN Comparison
Compare FDMT & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FDMT
- ENGN
- Stock Information
- Founded
- FDMT 2013
- ENGN 1999
- Country
- FDMT United States
- ENGN Canada
- Employees
- FDMT N/A
- ENGN N/A
- Industry
- FDMT Biotechnology: Pharmaceutical Preparations
- ENGN
- Sector
- FDMT Health Care
- ENGN
- Exchange
- FDMT Nasdaq
- ENGN Nasdaq
- Market Cap
- FDMT 268.6M
- ENGN 317.6M
- IPO Year
- FDMT 2020
- ENGN N/A
- Fundamental
- Price
- FDMT $4.64
- ENGN $6.29
- Analyst Decision
- FDMT Buy
- ENGN Buy
- Analyst Count
- FDMT 10
- ENGN 10
- Target Price
- FDMT $36.33
- ENGN $26.40
- AVG Volume (30 Days)
- FDMT 957.1K
- ENGN 179.7K
- Earning Date
- FDMT 03-03-2025
- ENGN 03-10-2025
- Dividend Yield
- FDMT N/A
- ENGN N/A
- EPS Growth
- FDMT N/A
- ENGN N/A
- EPS
- FDMT N/A
- ENGN N/A
- Revenue
- FDMT $17,000.00
- ENGN N/A
- Revenue This Year
- FDMT N/A
- ENGN N/A
- Revenue Next Year
- FDMT $159.36
- ENGN N/A
- P/E Ratio
- FDMT N/A
- ENGN N/A
- Revenue Growth
- FDMT N/A
- ENGN N/A
- 52 Week Low
- FDMT $4.41
- ENGN $4.42
- 52 Week High
- FDMT $36.25
- ENGN $18.40
- Technical
- Relative Strength Index (RSI)
- FDMT 40.01
- ENGN 44.90
- Support Level
- FDMT $4.41
- ENGN $5.51
- Resistance Level
- FDMT $5.42
- ENGN $7.00
- Average True Range (ATR)
- FDMT 0.48
- ENGN 0.74
- MACD
- FDMT -0.05
- ENGN -0.01
- Stochastic Oscillator
- FDMT 9.38
- ENGN 43.43
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.